Recce Pharmaceuticals (ASX:RCE) which is developing a new class of Synthetic Anti-Infectives, is nearing completion of its Phase II clinical trial of RECCE 327 Topical Gel (R327G) targeting Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
With 20 patients now dosed (of 30 total patients), interim data underscores R327G promising efficacy and safety profile.
Data demonstrates a strong therapeutic response, with all patients completing treatment with R327G achieving positive outcomes, showing either complete cure or notable improvement. No Serious Adverse Events (SAEs) have been reported for R327G.
"These interim results reflect a remarkable advancement in our journey to address critical unmet medical needs in anti-infective therapies,” Dr Alan Dunton, Chief Medical Advisor of Recce Pharmaceuticals, said.
“The robust response we are seeing with R327G is encouraging, especially as we near completion of the Phase II trial. Achieving a response of complete cure or notable improvement in all patients treated so far highlights the potential impact of R327G in treating complex bacterial infections, including diabetic foot infections.”
Dr Dunton said that as the trial progresses towards completion within CY2024, the company remains focused on delivering a pioneering, synthetic anti-infective topical therapy to address ABSSSI, a market estimated to reach US$26 billion by 2032.
“This continuation, following the non-DSMB’s unanimous endorsement, reflects the positive trajectory of R327G’s development and supports its continued progress toward regulatory evaluation.”
